General Hospital Bolzano, Bolzano, Italy.
J Urol. 2010 Nov;184(5):1895-900. doi: 10.1016/j.juro.2010.06.106. Epub 2010 Sep 17.
Tumor necrosis is associated with a poor oncological outcome in patients with upper tract urothelial carcinoma and other malignancies. We validated the association of tumor necrosis with pathological features and clinical outcomes in a large international cohort of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.
This retrospective study included 754 patients treated with radical nephroureterectomy at a total of 9 centers. Tumor necrosis was scored as greater than 10% of tumor area based on microscopic evaluation.
Tumor necrosis was present in 165 specimens (21.9%). The prevalence of tumor necrosis increased with advancing pathological stage, including 7%, 10.6% and 50% for T1, T2 and T3-4, respectively (p <0.001). Tumor necrosis was associated with features of aggressive upper tract urothelial carcinoma, such as high grade, lymph node metastasis, lymphovascular invasion, sessile tumor architecture and concomitant carcinoma in situ (p <0.002). Median followup in censored patients was 40 months (IQR 18 to 75). On univariate Cox regression analysis tumor necrosis was significantly associated with disease recurrence and cancer specific mortality (HR 2.4 and 2.7, p <0.001). However, on multivariate Cox regression analysis including patient age, stage, grade, lymph node status, lymphovascular invasion and adjuvant chemotherapy tumor necrosis was not associated with disease recurrence (HR 1.1, p = 0.49) or cancer specific mortality (HR 1.1, p = 0.51). Excluding 63 patients who received adjuvant chemotherapy and/or 49 with positive lymph nodes did not substantially change these results.
In this large, multicenter international study tumor necrosis was associated with pathological features of biologically aggressive upper tract urothelial carcinoma. However, tumor necrosis was not an independent predictor of clinical outcomes.
肿瘤坏死与上尿路上皮癌和其他恶性肿瘤患者的不良肿瘤学结果相关。我们通过对接受根治性肾输尿管切除术治疗的上尿路上皮癌患者的大型国际队列进行验证,以确定肿瘤坏死与病理特征和临床结果的相关性。
本回顾性研究纳入了 9 个中心共 754 例接受根治性肾输尿管切除术的患者。根据显微镜评估,肿瘤坏死评分大于肿瘤面积的 10%。
165 例标本(21.9%)存在肿瘤坏死。肿瘤坏死的发生率随病理分期的进展而增加,T1、T2 和 T3-4 分别为 7%、10.6%和 50%(p<0.001)。肿瘤坏死与侵袭性上尿路上皮癌的特征相关,如高级别、淋巴结转移、脉管侵犯、附壁肿瘤结构和同时存在原位癌(p<0.002)。在删失患者中,中位随访时间为 40 个月(IQR 18 至 75)。单因素 Cox 回归分析显示,肿瘤坏死与疾病复发和癌症特异性死亡显著相关(HR 2.4 和 2.7,p<0.001)。然而,在包括患者年龄、分期、分级、淋巴结状态、脉管侵犯和辅助化疗在内的多因素 Cox 回归分析中,肿瘤坏死与疾病复发(HR 1.1,p=0.49)或癌症特异性死亡(HR 1.1,p=0.51)无关。排除 63 例接受辅助化疗和/或 49 例淋巴结阳性的患者并没有显著改变这些结果。
在这项大型、多中心国际研究中,肿瘤坏死与具有生物学侵袭性的上尿路上皮癌的病理特征相关。然而,肿瘤坏死不是临床结果的独立预测因素。